Tcg Crossover Gp Ii, Llc Sells 325,000 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the firm’s stock in a transaction on Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total value of $6,906,250.00. Following the transaction, the insider directly owned 574,047 shares of the company’s stock, valued at $12,198,498.75. The trade was a 36.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Surrozen Trading Down 1.0%

Shares of SRZN stock opened at $19.20 on Thursday. Surrozen, Inc. has a twelve month low of $8.70 and a twelve month high of $35.00. The company has a market capitalization of $222.91 million, a price-to-earnings ratio of -0.51 and a beta of 0.51. The firm has a 50-day moving average price of $23.44 and a 200 day moving average price of $25.28.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($11.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($10.56). The firm had revenue of $5.00 million for the quarter, compared to analyst estimates of $4.00 million. As a group, research analysts predict that Surrozen, Inc. will post -7.2 earnings per share for the current year.

Institutional Trading of Surrozen

Hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its stake in shares of Surrozen by 50.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Surrozen in the 4th quarter worth approximately $99,000. Citadel Advisors LLC lifted its position in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the period. Marshall Wace LLP bought a new position in Surrozen during the fourth quarter valued at about $247,000. Finally, Geode Capital Management LLC boosted its position in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares in the last quarter. 66.57% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on SRZN. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a report on Friday, July 17th. Zacks Research downgraded Surrozen from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. HC Wainwright reiterated a “buy” rating and set a $44.00 target price (up from $36.00) on shares of Surrozen in a report on Thursday, May 7th. Finally, TD Cowen started coverage on shares of Surrozen in a research note on Tuesday, April 21st. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.